Form 4: Edwards Lifesciences SVP Receives Stock Grant

Edwards Lifesciences' SVP, Corporate Controller Andrew M. Dahl, was granted 1,160 restricted stock units and acquired shares through an employee stock purchase plan.

Summary

• Andrew M. Dahl, SVP, Corporate Controller of Edwards Lifesciences Corp (EW), reported changes in beneficial ownership.
• Dahl was granted 1,160 shares of Common Stock as restricted stock units (RSUs) on November 13, 2025, at a price of $0.0000 per share.
• These RSUs are part of the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.
• The RSUs are scheduled to vest and become exercisable commencing one year after the grant date (November 13, 2025) in four equal annual installments.
• Following these transactions, Dahl beneficially owns 9,183.074 shares of Common Stock directly.
• The filing also includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The filing reflects a routine executive compensation event, which is generally a neutral to slightly positive signal as it indicates ongoing executive alignment with company performance and retention efforts.

Positives

• The grant of restricted stock units aligns management's interests with shareholder value by providing equity-based compensation.
• Participation in the Employee Stock Purchase Plan indicates ongoing employee investment in the company.

Future Outlook

The restricted stock units granted to Andrew M. Dahl are scheduled to vest and become exercisable commencing one year after the grant date in four equal annual installments, indicating a future staggered release of equity.

Industry Context

The grant of restricted stock units is a common practice in the medical technology industry, including companies like Edwards Lifesciences, to incentivize and retain key executives by aligning their long-term interests with company performance and shareholder returns.

Comparison to Industry Standards

• Equity compensation through restricted stock units is a standard component of executive compensation packages across the S&P 500 and particularly within the medical device sector, comparable to practices at companies like Medtronic, Abbott Laboratories, and Boston Scientific, which also utilize long-term incentive programs to retain talent and drive performance.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the interests of a key executive with long-term shareholder value.
• Employees: The inclusion of an Employee Stock Purchase Plan indicates broad-based employee participation in company ownership.

Next Steps

• The restricted stock units will begin vesting one year from the grant date (November 13, 2025) in four equal annual installments.

Key Dates

Keywords

Edwards Lifesciences, EW, Restricted Stock Units, RSU, Insider Transaction, Form 4, Employee Stock Purchase Plan, Executive Compensation, Stock Grant